PETITION FOR EXTENSION OF TIME

Applicants hereby request a one-month extension of time extending the time for response from January 7, 1997 up to and including February 7, 1997. The Assistant Commissioner is hereby authorized to charge the required $110.00 fee to Deposit Account No. 23-1703. Any additional fees due in connection with this Petition should likewise be charged.

Please amend the application as follows:

In the Claims:

~~8~~ 17. (twice amended) [A] The method [for the treatment of asthma and other inflammatory respiratory disorders, which comprises administering by inhalation to a host in need of such treatment effective amounts of a physiologically acceptable salt of formoterol or a solvate thereof, and budesonide] according to claim ~~1~~ 17, wherein the effective amount of the physiologically acceptable salt of formoterol or solvate thereof is 6-100 μg per day, and the effective amount of budesonide is 50-4800 μg per day.

Please add the following new claims:

~~20~~ 29. The method according to any one of claims ~~1~~ 17, ~~17~~ 18 and ~~18~~ 19, wherein the physiologically acceptable salt of

formoterol or the solvate thereof is administered in admixture with the budesonide.

9 ~~30.~~ A medicament containing as active ingredients effective amounts of a physiologically acceptable salt of formoterol or a solvate thereof, and budesonide wherein the molar ratio of the formoterol component to the budesonide component is in the range from 1:1 to 1:60.

12 ~~31.~~ A pharmaceutical composition which comprises effective amounts of a physiologically acceptable salt of formoterol or a solvate thereof, and budesonide wherein the molar ratio of the formoterol component to the budesonide component is in the range from 1:1 to 1:60, together with a pharmaceutically acceptable carrier.

27 ~~32.~~ A method for the treatment of asthma and other inflammatory respiratory disorders which comprises administering by inhalation to a host in need of such treatment effective amounts of a physiologically acceptable salt of formoterol or a solvate thereof, and budesonide wherein the molar ratio of the formoterol component to the budesonide component is in the range from 1:1 to 1:60.

12 cont.

10 ~~33.~~ The medicament of claim 9 ~~30~~ wherein the active ingredients are in dry powder form.

11 ~~34.~~ The medicament of claim 9 ~~30~~ or 10 ~~33~~ wherein the formoterol is in the form of the fumarate dihydrate.

~~35~~ 13. The pharmaceutical composition of claim ~~31~~ 12 wherein the formoterol is in the form of the fumarate dihydrate.

~~36~~ 28. The method according to claim ~~32~~ 27, wherein the effective amount of the physiologically acceptable salt of formoterol or solvate thereof is 6-100 μg per day, and the effective amount of budesonide is 50-4800 μg per day.

~~37~~ 29. The method according to claim ~~36~~ 28 wherein the effective amount of the physiologically acceptable salt of formoterol or solvate thereof is 6-48 μg per day, and the effective amount of budesonide is 100-1600 μg per day.

~~38~~ 30. The method according to any one of claims ~~32~~ 27, ~~36~~ 28 and 37 wherein the administration is performed from a dry powder inhaler.

~~39~~ 31. The method according to claim ~~38~~ 30 wherein the inhaler is a Turbuhaler™.

~~40~~ 32. The method according to any one of claims ~~32~~ 27, ~~36~~ 28 and ~~37~~ 29 wherein the administration is performed from a metered dose inhaler.

32 cont

~~41~~ 33. The method according to any one of claims ~~32~~ 27, ~~36~~ 28 and ~~37~~ 29 wherein the formoterol is in the form of the fumarate dihydrate.

~~42~~ 14. A pharmaceutical composition according to claim ~~31~~ 12 wherein the pharmaceutically acceptable carrier is lactose.